Comment from Cystic Fibrosis Foundation

Summary: The Cystic Fibrosis Foundation supports the development of innovative therapies but urges the FDA to temporarily pause the CNPV pilot program to process stakeholder feedback and ensure consistent standards. They also recommend using the formal notice-and-comment process for future rules, increasing transparency in the selection process, removing political influence from the review council, and excluding pricing or manufacturing criteria from eligibility.